The novel anti-rheumatic drug TA-383 has a macrophage migration enhancing activity

Japanese Journal of Pharmacology

Volumn 74, Issue 2, 1997, Pages 221-224

  Ueno, Makoto ^a   Sugita, Takahisa ^a   Murakami, Takanori ^a   Takata, Isao ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Collagen induced arthritis; Macrophage migration enhancement activity; TA 383

Indexed keywords

2 (4 CHLOROPHENYL) 4,5 DIPHENYL 2 IMIDAZOLINE; ANTIRHEUMATIC AGENT; BUCILLAMINE; COLLAGEN TYPE 2; CYTOKINE; FUCOSE; LOBENZARIT; PICRYL CHLORIDE; SALAZOSULFAPYRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; SPLEEN CELL;

EID: 0030811201     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.221     Document Type: Article

References (15)

1. Bloom BR and Bennett B: Mechanisms of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80-82 (1966)
2. David JR and David RA: Cellular hypersensitivity and immunity: inhibition of macrophage migration and the lymphocyte mediators. Prog Allergy 16, 300-449 (1972)
3. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC and David JR: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 86, 7522-7526 (1989)
4. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, Gerhards G, Schlegel R and Sorg C: Two calcium-binding proteins in infiltrate macrophage of rheumatoid arthritis. Nature 330, 80-82 (1987)
5. Weiser WY, Pozzi Lu-AnnM, Titus RG and David JR: Recombinant human migration inhibitory factor has adjuvant activity. Proc Natl Acad Sci USA 89, 8049-8052 (1992)
6. Weisbart RH, Bluestone R, Goldberg LS and Pearson CM: Migration enhancement factor: a new lymphokine. Proc Natl Acad Sci USA 71, 875-879 (1974)
7. Gordon MR, Takata I and Myrvik QN: Induction of a macrophage migration enhancement factor after desensitization of tuberculin-positive rabbits with purified protein derivative. Infect Immun 51, 134-140 (1986)
8. Takata I, Chida K, Gordon MR, Myrvik QN, Ricardo MJ and Kucera LS: L-Fucose, D-mannose, L-garactose, and their BSA conjugates stimulate macrophage migration. J Leukocyte Biol 41, 248-256 (1987)
9. Gordon MR, Chida K, Takata I and Myrvic QN: Macrophage migration inhibitory induced by MDP, LPS, PMA, and MIF/MAF: Reversal by macrophage migration enhancement factor (MEF), L-fucose, L-fucose BSA, D-mannose, and D-mannosyl BSA. J Infect Immun 42, 197-203 (1987)
10. Ueno M, Sugita T, Furukawa O, Murakami T and Takata I: Immunopharmacological studies on a new antirheumatic drug, TA-383. Jpn J Pharmacol 58, Supp I, 123P (1992)
11. Sato K and Kashiwazaki S: Effects of TA-383 on the proliferation of rheumatoid synovium. Jpn J Inflamm 12, 573-574 (1992)
12. Sugita T, Ueno M, Furukawa O, Murakami T, Takata I and Tosa T: Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis-Suppressive of TA-383 on interleukin-6 production. Int J Immunophamacol 15, 515-519 (1993)
13. McGee MP and Myrvik QN: Collection of alveolar macrophage for rabbit lungs. In Manual of Macrophage Methodology, Edited by Herscowitz HB, Holden HT, Bellanti JA and Ghaffar A, p 17, Marcel Dekker, New Yowk (1981)
14. Ueno M, Imaizumi K, Sugita T, Takata I and Takesita M: Effect of a novel antirheumatic drug, TA-383, on type II collagen-induced arthritis. Int J Immunophamacol 17, 597-603 (1995)
15. Yamamoto I, Ohmori H and Sasano M: CCA: an immunopharmacological profile in vivo and in vitro. Drugs Exp Clin Res 8, 5-10 (1982)